Neogenix Oncology, Inc. announced that the Johns Hopkins Hospital has initiated a Phase I trial with the company’s first therapeutic antibody, NPC-1C, in patients with late stage pancreatic or colorectal cancer.
NPC-1C is a novel, chimeric monoclonal antibody intended for the treatment of advanced pancreatic and colorectal cancer, and is the first of the Neogenix pipeline of antibodies that target specific cancers. Pre-clinical studies have demonstrated that NPC-1 specifically targets pancreatic and colorectal cancer sparing healthy tissue.
“We are pleased to partner with the investigators at Johns Hopkins on this study and we look forward to fostering the relationship for future Neogenix therapeutic development. There is a serious need for new therapies for life-threatening illnesses, especially pancreatic cancer where very few treatment options exist. Having a treatment that would target the cancer specifically and spare healthy organs would represent a significant advancement in the treatment of this disease,” said Neogenix President and Chief Medical Officer, Philip M. Arlen, MD.
Neogenix Oncology is a cancer therapeutics and diagnostic company focused on developing new products targeting a broad range of cancers. The company’s portfolio includes monoclonal antibodies that have been shown to target tumor-specific immunogenic proteins derived from specific tumor subtypes.
Neogenix Oncology monoclonal antibodies are in that they define the immunogenic tumor protein as both a diagnostic marker and as a therapeutic target for tumor destruction. This revolutionary approach could offer patients a new range of therapeutic alternatives in the future.